It wasn’t exactly the way that California-based Jazz Pharmaceuticals wanted to start the week.
On Monday, October 11, word came through from the Food & Drug Administration that it had rejected the company’s fibromyalgia treatment called JZP-6.
The reason? Turns out it contains sodium oxybate – an active ingredient in GHB, also known as “the date rape drug.”
http://www.investmentu.com/2010/December/when-an-fda-rejection-is-a-good-thing.html
No comments:
Post a Comment